X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Aventis Pharma with Dishman Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SANOFI INDIA vs DISHMAN PHARMA - Comparison Results

SANOFI INDIA    Change

Sanofi India (the erstwhile Aventis Pharma), the 60% subsidiary of Sanofi-Aventis SA, France, is one of the largest pharma MNCs in India with a turnover of over Rs 13.2 bn in CY11. Domestic sales constituted 81% of total sales in CY11 and exports con... More

DISHMAN PHARMA 
   Change

Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SANOFI INDIA DISHMAN PHARMA SANOFI INDIA/
DISHMAN PHARMA
 
P/E (TTM) x 37.7 25.1 150.1% View Chart
P/BV x 7.1 3.3 212.1% View Chart
Dividend Yield % 0.5 0.7 80.5%  

Financials

 SANOFI INDIA   DISHMAN PHARMA
EQUITY SHARE DATA
    SANOFI INDIA
Dec-17
DISHMAN PHARMA
Mar-16
SANOFI INDIA/
DISHMAN PHARMA
5-Yr Chart
Click to enlarge
High Rs4,945374 1,320.8%   
Low Rs3,901129 3,026.4%   
Sales per share (Unadj.) Rs1,081.8197.8 546.9%  
Earnings per share (Unadj.) Rs141.621.2 667.5%  
Cash flow per share (Unadj.) Rs185.934.7 535.5%  
Dividends per share (Unadj.) Rs33.002.00 1,650.0%  
Dividend yield (eoy) %0.70.8 93.9%  
Book value per share (Unadj.) Rs868.8179.9 483.0%  
Shares outstanding (eoy) m23.0380.69 28.5%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.11.3 321.4%   
Avg P/E ratio x31.211.9 263.3%  
P/CF ratio (eoy) x23.87.2 328.2%  
Price / Book Value ratio x5.11.4 363.9%  
Dividend payout %23.39.4 247.2%   
Avg Mkt Cap Rs m101,86220,306 501.6%   
No. of employees `0003.20.8 390.7%   
Total wages/salary Rs m3,6855,355 68.8%   
Avg. sales/employee Rs Th7,691.919,252.7 40.0%   
Avg. wages/employee Rs Th1,137.76,459.5 17.6%   
Avg. net profit/employee Rs Th1,006.52,064.1 48.8%   
INCOME DATA
Net Sales Rs m24,91415,961 156.1%  
Other income Rs m807265 304.1%   
Total revenues Rs m25,72116,226 158.5%   
Gross profit Rs m5,3724,103 130.9%  
Depreciation Rs m1,0221,091 93.7%   
Interest Rs m11944 1.2%   
Profit before tax Rs m5,1462,334 220.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m01 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,886624 302.4%   
Profit after tax Rs m3,2601,711 190.5%  
Gross profit margin %21.625.7 83.9%  
Effective tax rate %36.626.7 137.1%   
Net profit margin %13.110.7 122.1%  
BALANCE SHEET DATA
Current assets Rs m14,43211,018 131.0%   
Current liabilities Rs m6,0109,517 63.2%   
Net working cap to sales %33.89.4 359.5%  
Current ratio x2.41.2 207.4%  
Inventory Days Days61110 55.1%  
Debtors Days Days2835 81.8%  
Net fixed assets Rs m7,99116,304 49.0%   
Share capital Rs m230161 142.7%   
"Free" reserves Rs m19,77812,907 153.2%   
Net worth Rs m20,00814,516 137.8%   
Long term debt Rs m04,189 0.0%   
Total assets Rs m27,77029,805 93.2%  
Interest coverage x468.83.5 13,506.8%   
Debt to equity ratio x00.3 0.0%  
Sales to assets ratio x0.90.5 167.5%   
Return on assets %11.88.9 132.2%  
Return on equity %16.311.8 138.2%  
Return on capital %25.817.5 147.0%  
Exports to sales %024.8 0.0%   
Imports to sales %03.7 0.0%   
Exports (fob) Rs mNA3,956 0.0%   
Imports (cif) Rs mNA596 0.0%   
Fx inflow Rs m6,3064,952 127.4%   
Fx outflow Rs m5,257697 754.4%   
Net fx Rs m1,0494,255 24.7%   
CASH FLOW
From Operations Rs m4,3512,786 156.2%  
From Investments Rs m-787-1,529 51.5%  
From Financial Activity Rs m-1,884-941 200.2%  
Net Cashflow Rs m1,680316 531.0%  

Share Holding

Indian Promoters % 0.0 61.4 -  
Foreign collaborators % 60.4 0.0 -  
Indian inst/Mut Fund % 14.4 3.7 389.2%  
FIIs % 14.6 12.7 115.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.5 22.1 47.5%  
Shareholders   15,184 46,261 32.8%  
Pledged promoter(s) holding % 0.0 35.8 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SANOFI INDIA With:   GSK PHARMA  JUBILANT LIFE SCIENCES  BIOCON LTD  IPCA LABS  NATCO PHARMA  

Compare SANOFI INDIA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Opens in Green; Hero MotoCorp & Sun Pharma Top Gainers(09:30 am)

Asian stock markets are higher today as Japanese and Hong Kong shares show gains. The Nikkei 225 is up 0.3% while the Hang Seng is up 0.2%.

Related Views on News

SANOFI INDIA Announces Quarterly Results (2QFY19); Net Profit Up 2.5% (Quarterly Result Update)

Nov 6, 2018 | Updated on Nov 6, 2018

For the quarter ended September 2018, SANOFI INDIA has posted a net profit of Rs 1 bn (up 2.5% YoY). Sales on the other hand came in at Rs 7 bn (up 11.4% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

SANOFI INDIA Announces Quarterly Results (1QFY19); Net Profit Up 35.1% (Quarterly Result Update)

Jul 27, 2018 | Updated on Jul 27, 2018

For the quarter ended June 2018, SANOFI INDIA has posted a net profit of Rs 996 m (up 35.1% YoY). Sales on the other hand came in at Rs 7 bn (up 13.8% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

These Are the Kind of Blue Chips You Should Invest In(The 5 Minute Wrapup)

Nov 9, 2018

All blue chip companies are large caps but all large caps are not blue chips.

Get this Small Cap Logistics Company at a 16% Discount Right Now...(Profit Hunter)

Nov 6, 2018

If you turn the clock back, the current macroeconomic climate is nothing new. The markets have seen them all, and every downcycle has been succeeded by gravity defying gains...more so in the small cap space. This time will be no different.

Insider Buying: These Owner Operators Are Taking Advantage of the Correction(Chart Of The Day)

Nov 2, 2018

We believe insider buying is one of the strongest smart money indicators.

Are Fund Houses Opening Up Their NFO Factories Again?(Outside View)

Nov 2, 2018

PersonalFN sheds light on FY 2018-19 so far, the mutual fund industry has collectively launched 84 New Fund Offers (NFOs), of which some are still open for subscription.

Does it Make Sense to Invest in Offshore Funds?(Outside View)

Nov 6, 2018

Many investors prefer to invest in offshore funds because of the rupee depreciation and on-going downtrend in the markets, but it is to be invested only when there is no option available to invest in India.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

SANOFI INDIA SHARE PRICE


Nov 15, 2018 11:47 AM

TRACK SANOFI INDIA

  • Track your investment in SANOFI INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SANOFI INDIA 8-QTR ANALYSIS

COMPARE SANOFI INDIA WITH

MARKET STATS